Status:
COMPLETED
Development of a New Immunochemistry Method Using Antibodies of Proteins Related Pancreatic Cancer
Lead Sponsor:
Gangnam Severance Hospital
Conditions:
Pancreatic Cancer
Eligibility:
All Genders
19+ years
Phase:
NA
Brief Summary
Identifying the malignancy of pancreatic mass using endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) is important for treatment decision-making and prognosis prediction. The sensitivity o...
Detailed Description
BACKGROUND / AIMS: The sensitivity of endoscopic ultrasound-guided aspiration cytology used to distinguish the pancreatic mass is low and clinical usefulness is not secured. The aim of this study was ...
Eligibility Criteria
Inclusion
- Patients with pancreatic cancer confirmed by imaging (CT, MRI, PET-CT)
- Patients with pancreatic cancer diagnosed using cytology by endoscopic ultrasound
- Patients who underwent surgical treatment with pancreatic cancer
Exclusion
- Minors under the age of 19, vulnerable subjects such as illiteracy
- Excludes necrotic specimens
- Samples with non-diagnostic cytology results and insufficient cells for further evaluation
- Samples classified as neoplastic (benign or other)
Key Trial Info
Start Date :
February 17 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
July 2 2021
Estimated Enrollment :
97 Patients enrolled
Trial Details
Trial ID
NCT04293497
Start Date
February 17 2020
End Date
July 2 2021
Last Update
August 13 2021
Active Locations (4)
Enter a location and click search to find clinical trials sorted by distance.
1
CHA Bundang Medical Center
Seongnam, Bundang-gu, South Korea, 13496
2
Gangnam Severance Hospital
Seoul, Gangnam-gu, South Korea, 06229
3
In Ha University Hospital
Incheon, Jung-gu, South Korea, 22332
4
Soon Chun Hyang University Hospital, Cheonan
Cheonan, Namdong-gu, South Korea, 31151